MarketCapExport financials
Lineage Cell Therapeutics (LCTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Lineage Cell Therapeutics Balance Sheet 2025-2008 | LCTX
Brief overview of Lineage Cell Therapeutics's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets declined from $174.5 million to $112.6 million, or -35.5%. The contraction calls for context such as disposals, restructuring or weaker operations.
Funding shifted toward liabilities: they gained -17.2%, compared with -35.5% for assets.
The share of internal funding stands at 39.6% versus 52.8% initially, providing a reasonable foundation.
The balance sheet holds more cash than interest-bearing debt; net debt is -$39.9 million, indicating minimal leverage.
Cash represents 36.2% of assets versus 31.9% initially, showing how the immediate liquidity reserve changed.
The balance sheet carries negative retained earnings of -$467 million. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
The balance sheet gives no single signal for Lineage Cell Therapeutics: some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet Lineage Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-39.9 M | -44.6 M | -34.5 M | -10.4 M | -54.9 M | -28.8 M | -4.33 M | -21.3 M | -36.7 M | -20 M | -41.6 M | -29 M | -5.5 M | -4.35 M | -22.2 M | - | - | - |
Long Term Debt |
32 K | 67 K | 91 K | 84 K | 30 K | - | - | - | 18 K | 1.15 M | 544 K | - | - | - | - | - | - | - |
Long Term Debt Current |
816 K | 1.1 M | 830 K | 916 K | 801 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 5.05 M | 7.74 M | 2.6 M | 2.1 M | 3.21 M | 5.75 M | 5.05 M | 8.51 M | 1.06 M | 1.22 M | 1.37 M | - | - |
Total Current Liabilities |
11.4 M | 14 M | 18 M | 19 M | 47.1 M | 7.77 M | 6.49 M | 6.81 M | 6.88 M | 8.85 M | 12.5 M | 7.13 M | 6.96 M | 4.39 M | 3.15 M | 2.48 M | - | - |
Total Liabilities |
69.2 M | 36.2 M | 39 M | 51.7 M | 83.6 M | 12.8 M | 14.2 M | 9.41 M | 8.98 M | 12.1 M | 18.2 M | 12.2 M | 15.5 M | 5.45 M | 4.37 M | - | - | - |
Deferred Revenue |
3.33 M | 7.39 M | 10.8 M | 9.42 M | 18.1 M | 193 K | 45 K | 42 K | 797 K | 572 K | 2.95 M | 208 K | 235 K | 401 K | 466 K | 288 K | - | - |
Retained Earnings |
-467 M | -403 M | -385 M | -363 M | -337 M | -294 M | -273 M | -262 M | -216 M | -196 M | -229 M | -182 M | -146 M | -102 M | -80.5 M | -64 M | - | - |
Total Assets |
113 M | 113 M | 101 M | 124 M | 175 M | 108 M | 125 M | 102 M | 173 M | 143 M | 94.7 M | 74.9 M | 57.7 M | 29.7 M | 45.8 M | 53.3 M | - | - |
Cash and Cash Equivalents |
40.8 M | 45.8 M | 35.4 M | 11.4 M | 55.7 M | 32.6 M | 9.5 M | 23.6 M | 36.8 M | 22.1 M | 42.2 M | 29.5 M | 5.5 M | 4.35 M | 22.2 M | 33.3 M | 12.2 M | 12.3 K |
Book Value |
43.3 M | 77 M | 62 M | 71.9 M | 90.9 M | 95.1 M | 111 M | 92.2 M | 164 M | 131 M | 76.4 M | 62.7 M | 42.3 M | 24.3 M | 41.5 M | 53.3 M | - | - |
Total Shareholders Equity |
44.5 M | 78.4 M | 63.4 M | 73.3 M | 92.2 M | 96.2 M | 113 M | 93.8 M | 163 M | 118 M | 26.9 M | 36.5 M | 14.8 M | 9.58 M | 28.6 M | 38.2 M | 11 M | -4.35 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Lineage Cell Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
15 K | 22 K | 40 K | 48 K | 51 K | 67 K | 80 K | 68 K | 79 K | 91 K | 97 K | 113 K | 133 K | 84 K | 16 K | 19 K | 26 K | 30 K | 12 K | 16 K | 26 K | 26 K | 26 K | 26 K | 26 K | 77 K | 77 K | 77 K | 77 K | 104 K | 104 K | 104 K | 104 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.5 M | 18.2 M | 5.59 M | 5.47 M | 3.99 M | 5.11 M | 5.05 M | 5.05 M | 5.05 M | 8.51 M | 8.51 M | 8.51 M | 8.51 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M |
Total Liabilities |
46.4 M | 56.8 M | 68.8 M | 43.7 M | 34.1 M | 36.2 M | 31.8 M | 35.9 M | 37.5 M | 39 M | 39.5 M | 40.4 M | 44.2 M | 51.7 M | 53.6 M | 54.4 M | 59.3 M | 83.6 M | 11.6 M | 11.2 M | 11.4 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 9.41 M | 9.41 M | 9.41 M | 9.41 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 18.2 M | 18.2 M | 18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.68 M | 1.72 M | 3.77 M | 5.26 M | 6.93 M | 7.39 M | 8.25 M | 9.14 M | 10.1 M | 10.8 M | 9.92 M | 10.4 M | 11 M | 9.42 M | 12.4 M | 15.8 M | 14.9 M | 18.1 M | 975 K | 613 K | 101 K | 193 K | 193 K | 297 K | 193 K | 45 K | 182 K | 45 K | 43 K | 42 K | 42 K | 103 K | 202 K | 309 K | 513 K | 309 K | 309 K | 572 K | 537 K | 572 K | 572 K | 439 K | 439 K | 439 K | 439 K | 208 K | 208 K | 208 K | 208 K | 235 K | 235 K | 235 K | 235 K | 401 K | 401 K | 401 K | 401 K | 204 K | 204 K | 204 K | 204 K |
Retained Earnings |
-470 M | -472 M | -468 M | -438 M | -408 M | -403 M | -400 M | -397 M | -391 M | -385 M | -380 M | -373 M | -368 M | -363 M | -357 M | -351 M | -344 M | -337 M | -308 M | -300 M | -295 M | -294 M | -294 M | -294 M | -294 M | -273 M | -273 M | -273 M | -273 M | -262 M | -262 M | -262 M | -262 M | -216 M | -216 M | -216 M | -216 M | -196 M | -196 M | -196 M | -196 M | -230 M | -229 M | -229 M | -229 M | -182 M | -182 M | -182 M | -182 M | -146 M | -146 M | -146 M | -146 M | -102 M | -102 M | -102 M | -102 M | -80.5 M | -80.5 M | -80.5 M | -80.5 M |
Total Assets |
106 M | 110 M | 89.6 M | 90.8 M | 112 M | 113 M | 96.6 M | 103 M | 108 M | 101 M | 106 M | 112 M | 113 M | 124 M | 131 M | 136 M | 145 M | 175 M | 131 M | 135 M | 128 M | 108 M | 108 M | 108 M | 108 M | 125 M | 125 M | 125 M | 125 M | 102 M | 102 M | 102 M | 102 M | 173 M | 173 M | 173 M | 173 M | 143 M | 143 M | 143 M | 143 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 57.7 M | 57.7 M | 57.7 M | 57.7 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M |
Cash and Cash Equivalents |
37.4 M | 35.9 M | 40.5 M | 42.3 M | 47.9 M | 45.8 M | 27.8 M | 29.6 M | 43.6 M | 35.4 M | 31.5 M | 33.9 M | 15.5 M | 11.4 M | 24.8 M | 70.9 M | 78.1 M | 55.7 M | 60.8 M | 62 M | 56.2 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 36.8 M | 36.8 M | 36.8 M | 36.8 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 42.2 M | 42.2 M | 42.2 M | 42.2 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 4.35 M | 4.35 M | 4.35 M | 4.35 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M |
Book Value |
59.8 M | 52.7 M | 20.8 M | 47.1 M | 77.7 M | 77 M | 64.8 M | 66.9 M | 71 M | 62 M | 66.7 M | 71.3 M | 69 M | 71.9 M | 77.6 M | 81.5 M | 85.2 M | 90.9 M | 120 M | 124 M | 117 M | 95.1 M | 95.1 M | 95.1 M | 95.1 M | 111 M | 111 M | 111 M | 111 M | 92.2 M | 92.2 M | 92.2 M | 92.2 M | 164 M | 164 M | 164 M | 164 M | 131 M | 131 M | 131 M | 131 M | 76.4 M | 76.4 M | 76.4 M | 94.7 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 57.7 M | 57.7 M | 57.7 M | 57.7 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M |
Total Shareholders Equity |
60.9 M | 53.9 M | 22 M | 48.4 M | 79 M | 78.4 M | 64.8 M | 66.9 M | 71 M | 63.4 M | 66.7 M | 71.3 M | 69 M | 73.3 M | 77.6 M | 81.5 M | 85.2 M | 92.2 M | 120 M | 124 M | 117 M | 96.2 M | 96.2 M | 96.2 M | 96.2 M | 113 M | 113 M | 113 M | 113 M | 92.2 M | 93.8 M | 93.8 M | 93.8 M | 163 M | 163 M | 163 M | 163 M | 118 M | 118 M | 118 M | 118 M | 25.8 M | 26.9 M | 26.9 M | 26.9 M | 36.5 M | 36.5 M | 36.5 M | 36.5 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 9.58 M | 9.58 M | 9.58 M | 9.58 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Lineage Cell Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Israel
Britain
Irlanda
Singapore
Schweiz
